Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone510-871-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.19 million
Profitability
Miscellaneous
Employees113
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Gritstone Oncology (NASDAQ:GRTS) Frequently Asked Questions
What is Gritstone Oncology's stock symbol?
Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."
How were Gritstone Oncology's earnings last quarter?
Gritstone Oncology Inc (NASDAQ:GRTS) released its earnings results on Monday, August, 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.01. The company earned $1.15 million during the quarter, compared to analysts' expectations of $1.20 million. Gritstone Oncology had a negative net margin of 2,038.71% and a negative return on equity of 83.79%. View Gritstone Oncology's Earnings History.
When is Gritstone Oncology's next earnings date?
What price target have analysts set for GRTS?
8 equities research analysts have issued 1-year price objectives for Gritstone Oncology's stock. Their predictions range from $17.00 to $31.00. On average, they anticipate Gritstone Oncology's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 169.4% from the stock's current price. View Analyst Price Targets for Gritstone Oncology.
What is the consensus analysts' recommendation for Gritstone Oncology?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gritstone Oncology.
What are Wall Street analysts saying about Gritstone Oncology stock?
Here are some recent quotes from research analysts about Gritstone Oncology stock:
- 1. According to Zacks Investment Research, "Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patients tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients TSNA to drive the patients immune system to attack and destroy tumors. " (10/15/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of GRTS and our 12-month price target of $17.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected GRANITE-001 and SLATE-001 revenues through 2030, assuming a 12.5% discount rate and 3% terminal growth rate." (4/1/2019)
Has Gritstone Oncology been receiving favorable news coverage?
News stories about GRTS stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gritstone Oncology earned a news impact score of -2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Gritstone Oncology.
Are investors shorting Gritstone Oncology?
Gritstone Oncology saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 3,000,000 shares, a decrease of 5.1% from the August 15th total of 3,160,000 shares. Based on an average trading volume of 166,900 shares, the short-interest ratio is presently 18.0 days. Currently, 15.4% of the company's stock are short sold. View Gritstone Oncology's Current Options Chain.
Who are some of Gritstone Oncology's key competitors?
Some companies that are related to Gritstone Oncology include Editas Medicine (EDIT), Alector (ALEC), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), AVITA MED LTD/S (RCEL), Rubius Therapeutics (RUBY), Vericel (VCEL), Atara Biotherapeutics (ATRA), Osiris Therapeutics (OSIR) and Krystal Biotech (KRYS).
What other stocks do shareholders of Gritstone Oncology own?
Who are Gritstone Oncology's key executives?
Gritstone Oncology's management team includes the folowing people:
- Dr. Andrew R. Allen, Co-Founder, Pres, CEO & Director (Age 52)
- Dr. Karin Jooss, Exec. VP of Research & Chief Scientific Officer (Age 54)
- Prof. Raphaël F. Rousseau M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 50)
- Mr. Jean-Marc Bellemin M.B.A., Exec. VP of Fin. & CFO (Age 47)
- Dr. Roman Yelensky, Exec. VP & CTO (Age 40)
When did Gritstone Oncology IPO?
(GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Gritstone Oncology?
Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Gritstone Oncology's stock price today?
One share of GRTS stock can currently be purchased for approximately $7.92.
How big of a company is Gritstone Oncology?
Gritstone Oncology has a market capitalization of $283.30 million and generates $1.19 million in revenue each year. The company earns $-64,780,000.00 in net income (profit) each year or ($7.26) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe.View Additional Information About Gritstone Oncology.
What is Gritstone Oncology's official website?
How can I contact Gritstone Oncology?
Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at [email protected]
MarketBeat Community Rating for Gritstone Oncology (NASDAQ GRTS)
MarketBeat's community ratings are surveys of what our community members think about Gritstone Oncology and other stocks. Vote "Outperform" if you believe GRTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
